The pharmaceutical wholesale and distribution sector is the vital link between pharmaceutical companies and pharmacies. Growing demand for drugs worldwide is driving that sector's growth. However, many pressures and challenges have placed a premium on service and efficiency in pharma wholesale and distribution. What are the key issues involved? Who are the major players and how do their businesses operate? Where are the best opportunities to be found, and how could you unlock these? Our new report - Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2010-2025 - reveals where the most-exciting developments will lie from the present onwards.

Pharmaceutical wholesalers and distributers provide an often-overlooked service to the pharma industry, healthcare providers and patients. However, that sector is currently in transition. Is the traditional wholesale model really in decline? If so, how would it be superseded and how rapidly? Many countries are experiencing changes in the way drugs are distributed to retailers. Integration, consolidation and disintermediation are all altering the pharma supply chain. How does the sector function and what does the future hold for it and its stakeholders? Our new study provides the answers that you require.

In particular, Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2010-2025 examines following major issues:

Effects of the fee-for-service (FFS) switch
European price controls and parallel trade
Consolidation and integration of industry players
The importation of prescription drugs into the USA
Drug counterfeiting
The Internet - mail order drugs and on-line pharmacies
The threat of Wal-Mart
The three major US wholesalers - AmerisourceBergen, McKesson and Cardinal Health - analysis of revenues, margins and business structures
The three major European wholesalers - Alliance Boots, Celesio and the Phoenix Group - analysis of revenues, margins and business structures
Direct-pharmacy (DTP) trends, advantages and challenges
Overarching analyses of the European and US sectors.

Comprehensive analysis of pharmaceutical wholesale and distribution

Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2010-2025 critically examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This new report provides unique sales forecasts and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 85 tables and figures included, as well as an interview with a relevant authority. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy this Report?

This report gives you the following benefits in particular:

You will receive comprehensive information on the pharmaceutical wholesale sector, including how the industry works and how it is changing
You will review the important financial details for the US and European markets, including revenue forecasts for 2010 to 2025
You will examine financial information for the world's leading pharmaceutical wholesalers, including forecasts for 2010 to 2025
You will discover the effects of drug diversion, seeing how manufacturers are responding and assessing how effective those measures will be
You will explore how disintermediation is affecting the industry and who are benefitting in particular
You will determine the effects of market drivers and restraints on wholesalers' profits and overall commercial prospects
You will gain insight into the forces that influence the sector as a whole, as well as examination of those for the European and US sectors individually
You will receive expert opinion from our original survey of the sector.

You can obtain this report today

Nobody with an interest in pharmaceutical wholesaling, distribution or retail trade can afford to overlook this new study. We predict that this overall sector will see growth from 2010 onwards, with efficient, resilient and responsive organisations benefiting. Demand for pharmaceuticals is growing worldwide, but this driver alone will not be enough to ensure that wholesalers prosper. Diversification, integration and globalisation will all play their roles. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

1. Executive Summary
- 1.1 Aims of this Report
- 1.2 Brief Overview of the Chapters in This Report
2. Introduction to The Pharmaceutical Wholesale and Distribution Sector
- 2.1 An Overview
- 2.2 The Drug Wholesaler - More Than Just a Middleman
- 2.3 Roles and Functions of the W&D Companies
- 2.4 Types of Wholesaler
  - 2.4.1 Full-Line Wholesalers
  - 2.4.2 Short-Line Wholesalers
  - 2.4.3 Secondary Wholesalers
  - 2.4.4 Vertical Integration
- 2.5 The World Market Estimate and Forecast
3. Key Concepts in Pharmaceutical Wholesale and Distribution
- 3.1 Pharmaceutical Wholesale is Different from Other Forms of Wholesale
- 3.2 Business Models
  - 3.2.1 Gross Profit
  - 3.2.2 Forward Buying
  - 3.2.3 Fees-for-Service
  - 3.2.4 Discounts
  - 3.2.5 Inventory Management Agreements
- 3.3 Specialty Products
- 3.4 Reimbursement
- 3.5 Clawback
- 3.6 Pharmacy Benefit Managers
- 3.7 Diversion
  - 3.7.1 Re-importation
  - 3.7.2 Parallel Trade
- 3.8 Disintermediation
  - 3.8.1 Direct-to-Pharmacy
  - 3.8.2 Case study: Pfizer and Alliance Healthcare (Alliance Boots)
  - 3.8.3 Pfizer's DTP Discounts
  - 3.8.4 Internet Pharmacies
  - 3.8.5 Mail Order Pharmacies
  - 3.8.6 Supermarkets
- 3.9 Counterfeits
4.The US Pharmaceutical Wholesale and Distribution Market
- 4.1 Overview
- 4.2 Trade Associations
- 4.3 Legal Matters
- 4.4 The Fee-for-Service Switch
- 4.5 Where Do the Drugs End Up?
- 4.6 Re-importation of Pharmaceuticals
- 4.7 US Market Forecast
5. The Three Leading US Wholesalers
- 5.1 Overview
- 5.2 Consolidation and Market Share
- 5.3 US Big Three: Market Share Forecast
- 5.4 US Big Three: Earning Margins
- 5.5 Important Note on Dates and Data
- 5.6 AmerisourceBergen
  - 5.6.1 Divisions
  - 5.6.2 Customers
  - 5.6.3 Recent Performance
  - 5.6.4 Forecast and Analysis
- 5.7 Cardinal Health
  - 5.7.1 Divisions
  - 5.7.2 Customers
  - 5.7.3 Recent Performance
  - 5.7.4 Forecast and Analysis
- 5.8 McKesson Corporation
  - 5.8.1 Operating Segments
  - 5.8.2 Largest Customers
  - 5.8.3 Recent Performance
  - 5.8.4 Forecast and Analysis
6.The European Pharmaceutical Wholesale and Distribution Market
- 6.1 Overview
- 6.2 Trade Associations
- 6.3 Legal Issues
- 6.4 Major Differences between US and European Pharmaceutical Wholesale and Distribution Sectors
  - 6.4.1 Pharmaceutical Price Controls
  - 6.4.2 Parallel Imports
  - 6.4.3 State-Funded Healthcare and Reimbursement
  - 6.4.4 Generics
  - 6.4.5 A Single Market?
  - 6.4.6 Consolidation of European Pharmaceutical Wholesale Industry
  - 6.4.7 Independent Pharmacies are Rare in Parts of Europe
  - 6.4.8 Pre-wholesaling
  - 6.4.9 Direct-to-Pharmacy
  - 6.4.10 European Online Drug Sales are Low and Limited to OTC
  - 6.4.11 Accounting Practices
  - 6.4.12 Exchange Rate Information
- 6.5 European Pharmaceutical Wholesale and Distribution Market Forecast
7. The Three Leading European Wholesalers
- 7.1 Overview
- 7.2 Big Three: Market Share
- 7.3 Big Three: Market Share Forecast and Analysis
- 7.4 Alliance Boots
  - 7.4.1 Overview
  - 7.4.2 Divisions
  - 7.4.3 Margins
  - 7.4.4 Recent Performance
  - 7.4.5 Analysis and Forecast
- 7.5 Celesio
  - 7.5.1 Overview
  - 7.5.2 Divisions
  - 7.5.3 Revenue by Country
  - 7.5.4 Recent Performance
  - 7.5.5 Forecast and Analysis
- 7.6 The Phoenix Group
  - 7.6.1 Overview
  - 7.6.2 Group Members
  - 7.6.3 Revenue by Country
  - 7.6.4 Phoenix Group to be Sold?
  - 7.6.5 Recent Performance
    - 7.6.5.1 Phoenix Group
    - 7.6.5.2 Phoenix Pharmahandel (Germany)
    - 7.6.5.3 Tamro (Nine Scandinavian and Baltic Countries)
  - 7.6.6 Forecast and Analysis
8. Major Issues Affecting the Pharmaceutical Wholesale and Distribution Sector
- 8.1 Increased Demand for Pharmaceuticals
- 8.2 Specialty Drugs
- 8.3 Generics
- 8.4 Globalisation
- 8.5 Low Margins
- 8.6 Disintermediation
  - 8.6.1 Direct-to-Pharmacy
  - 8.6.2 Supermarkets
  - 8.6.3 Internet and Mail Order Pharmacies
- 8.7 Consolidation Throughout the Industry
- 8.8 Counterfeits
- 8.9 Reimbursement Issues
- 8.10 Diversion
9. Expert Opinion
- 9.1 Monika Derecque-Pois
  - 9.1.1 Importance of the Full-Line Wholesaler
  - 9.1.2 Challenges Facing the Industry
  - 9.1.3 Security of the Supply Chain and EU Legislation
  - 9.1.4 Detecting Counterfeits
10. Conclusions
- 10.1 Wholesalers are the Vital Link between Manufacturers and Retailers
- 10.2 Pharmaceutical Wholesaling is a Sector with High Revenues but Low Margins
- 10.3 The Pharmaceutical Wholesale and Distribution Industry is in a State of Transition
- 10.4 The Direct-to-Pharmacy Model Threatens Revenues but Guarantees Profits
- 10.5 The Industry's Main Driver is Increased Demand for Pharmaceuticals
- 10.6 Generics have Good Margins Now, But for How Long?
- 10.7 The US and European Pharmaceutical Wholesale Sectors are both Dominated by a Small Numbers of Large Wholesalers
- 10.8 Vertical Integration of Wholesalers and Retailers is Common in Europe
- 10.9 Consolidation Threatening Wholesalers Margins?
- 10.10 Diversion: Who Benefits?
- 10.11 There are No Easy Solutions to Stop Counterfeit Medicines
- 10.12 The Future of Pharma Wholesale and Distribution
List of Tables
- Table 2.1 Pharmaceutical Wholesale Industry: Worldwide and Area Revenue Forecasts, 2008-2025
- Table 4.1 The US Wholesale Industry: Breakdown by Sector, 2008
- Table 4.2 Number of States with Pedigree Legislation
- Table 4.3 HDMA Members: Customers by Revenue Share, 2008
- Table 4.4 HDMA Members: Revenue by Product Type, 2008
- Table 4.5 US Pharmaceutical Wholesale Market: Forecast, 2010-2025
- Table 4.6 Drivers and Restraints for the US Pharmaceutical Wholesale Industry, 2010
- Table 5.1 US Big Three: Revenues and Market Shares, 2008
- Table 5.2 US Big Three: Revenue and Market Share Forecast, 2010-2025
- Table 5.3 How Prescription Dollars are Spent, 2009
- Table 5.4 US Big Three: Revenue, Gross Profit and Net Income, 2008
- Table 5.5 US Big Three: Fiscal Years
- Table 5.6 AmerisourceBergen: Major Customers, Fiscal Year 2009
- Table 5.7 AmerisourceBergen: Revenues, Gross Profit and Net Income, 2005-2007
- Table 5.8 AmerisourceBergen: Revenue, Profit and Income Forecast, 2010-2025
- Table 5.9 Cardinal Health: Division Revenue and Income, Fiscal Year 2009
- Table 5.10 Cardinal Health: Customers by Contribution to Overall Revenues, Fiscal Year 2009
- Table 5.11 Cardinal Health: Revenue, Profit and Income, 2005-2009
- Table 5.12 Cardinal Health: Liabilities, Three Months to September 2009
- Table 5.13 Cardinal Health: Revenue, Profit and Income Forecast, 2010-2025
- Table 5.14 Cardinal Health: Revenue and Profit by Type of Customer, 2005-2009
- Table 5.15 McKesson: Division Revenue and Gross Profit, Fiscal Year 2009
- Table 5.16 McKesson: Customers by Contribution to Overall Revenues, Fiscal Year 2009
- Table 5.17 McKesson: Revenue, Profit and Income, 2005-2009
- Table 5.18 McKesson: Revenue, Profit and Income Forecast, 2010-2025
- Table 6.1 The European Pharmaceutical Wholesale Market by Type of Wholesaler, 2008
- Table 6.2 How Price Controls Vary Across Europe, 2009
- Table 6.3 How Pharmaceutical Retail Prices are Divided, by European Country, 2003/2004
- Table 6.4 Generic Market Share by Country, 2008
- Table 6.5 Number of Retail Pharmacies Owned by Three European Pharmaceutical Wholesalers, 2008
- Table 6.6 European Pharmaceutical Distribution Market: Forecast, 2010-2025
- Table 6.7 European Pharmaceutical Wholesale Market: Drivers and Restraints, 2010
- Table 7.1 The Big Three European Wholesalers: Revenues and Market Shares, 2008
- Table 7.2 European Big Three: Market Share Forecast, 2010-2025
- Table 7.3 Alliance Boots: Revenue and Trading Profit by Division, 2008
- Table 7.4 Alliance Boots: Division Profit Margins, 2008
- Table 7.5 Alliance Boots: Pro Forma Results, 2007-2009
- Table 7.6 Alliance Boots: Consolidated Results, 2007-2009
- Table 7.7 Alliance Boots: Effect of Financial Costs on Profits, 2008-2009
- Table 7.8 Alliance Boots: Revenue and Net Profit Forecast, 2010-2025
- Table 7.9 Where Celesio Operates, 2009
- Table 7.10 Celesio: Revenue, Gross Profit and Net Profit by Division, 2008
- Table 7.11 Celesio: Division Profit Margins, 2008
- Table 7.12 Celesio: Revenue by Country, 2008
- Table 7.13 Celesio: Revenue, Gross Profit and Net Profit, 2005-2009
- Table 7.14 Celesio: Revenue, Gross Profit and Net Profit Forecast, 2010-2025
- Table 7.15 Phoenix Group: Members and Locations, 2010
- Table 7.16 Phoenix Group: Revenue by Country, 2008
- Table 7.17 Phoenix Group: Revenues, 2005-2009
- Table 7.18: Phoenix Pharmahandel: Revenue and Income, 2005-2009
- Table 7.19 Tamro: Revenue, Operating Income and Net Profit, 2005-2009
- Table 7.20 Phoenix Group: Revenue Forecast, 2010-2025
- Table 8.1 SWOT Analysis of the Pharmaceutical Wholesale and Distribution Sector, 2010
- Table 8.2 Prevalence of the DTP Model in the UK, 2010
- Table 8.3 Counterfeit Incidents, 2008
- Table 8.4 Number of Counterfeit Incidents Recorded by PSI, 2002-2008
List of Figures
- Figure 2.1 Pharmaceutical Wholesale Industry: Revenue Forecast by Area, 2010-2025
- Figure 4.1 The Top Five US Wholesale Sectors by Revenue, 2008
- Figure 4.2 HDMA Members: Customers by Revenue Share, 2008
- Figure 4.3 HDMA Members: Revenue by Product Type, 2008
- Figure 4.4 US Pharmaceutical Wholesale Market: Forecast, 2010-2025
- Figure 5.1 US Pharmaceutical W&D Market by Share, 2008
- Figure 5.2 US Big Three: Revenue and Market Share Forecast, 2010-2025
- Figure 5.3 How Prescription Dollars are Spent: Share of $1 Spent on Prescription Drugs
- Figure 5.4 US Big Three: Revenue, Gross Profit and Net Income, 2008
- Figure 5.5 AmerisourceBergen: Divisions, 2009
- Figure 5.6 AmerisourceBergen: Customers by Share of Revenues, Fiscal Year 2009
- Figure 5.7 AmerisourceBergen: Revenue and Margins Forecast, 2010-2025
- Figure 5.8 Cardinal Health: Division Contribution to Revenue, Fiscal Year 2009
- Figure 5.9 Cardinal Health: Customers by Revenue Contribution, Fiscal Year 2009
- Figure 5.10 Cardinal Health: Bulk and Non-Bulk Sales Contribution to Revenue, 2005-2009
- Figure 5.11 Cardinal Health: Revenue and Margins Forecast, 2010-2025
- Figure 5.12 McKesson: Division Contribution to Revenue and Profit, Fiscal Year 2009
- Figure 5.13 McKesson: Customers by Contribution to Overall Revenues, Fiscal Year 2009
- Figure 5.14 McKesson: Revenue and Margins Forecast, 2010-2025
- Figure 6.1 Generic Penetration Rates by Percentage of Total Market Revenue: Selected European Countries and USA, 2008
- Figure 6.2 The European Pharmaceutical Wholesale Market: Forecast, 2010-2025
- Figure 7.1 Big Three European Wholesalers' Market Shares, 2008
- Figure 7.2 European Big Three: Revenue Forecast, 2010-2025
- Figure 7.3 Contributions of Alliance Boots' Divisions to Revenue and Trading Profit, 2008
- Figure 7.4 Alliance Boots: Revenue and Profit Margin Forecast, 2010-2025
- Figure 7.5 Contributions of Celesio's Divisions to Revenue, 2008
- Figure 7.6 Celesio: Revenue by Country, 2008
- Figure 7.7 Celesio: Revenue and Margins Forecast, 2010-2025
- Figure 7.8 Phoenix Group: Revenue by Country, 2008
- Figure 7.9 Comparisons of Revenues of Tamro, Phoenix Pharmahandel and Phoenix Group, 2005-2009
- Figure 7.10 Phoenix Group: Revenue Forecast, 2010-2025
- Figure 8.1 Counterfeit Incidents by Area, 2008
- Figure 8.2 Number of Counterfeit Incidents Recorded by PSI, 2002-2008
Companies Listed
- A1 Pharmaceuticals plc
- AAH Pharmaceuticals Ltd
- AB Acquisitions Ltd
- Actavis Group hf
- Alliance Boots plc.
- Alliance Healthcare
- Alliance Santé
- Alliance UniChem
- Almus
- American Health Packaging
- AmerisourceBergen Corporation
- AmerisourceBergen Packaging Group
- AmerisourceBergen Specialty Group
- Anderson Packaging
- Andreae-Noris Zahn AG
- ARmark Authentication Technologies LLC
- Astellas
- AstraZeneca
- Bayer Schering
- Boots the Opticians
- Brecon Pharmaceuticals
- Bristol Myers Squibb
- British Association of Pharmaceutical Wholesalers (BAPW)
- Cardinal Health Inc.
- CareFusion Corporation
- Caremark Rx
- Celesio AG
- Central Homecare
- Centre for Disease Control (CDC)
- Centre for Medicines in the Public Interest (CMPI)
- Colorcon, Inc
- CVS Caremark
- CVS Corporation
- Department of Veterans Affairs (VA)
- DocMorris
- Dollond and Aitchison
- Eli Lilly
- European Association of Euro-Pharmaceutical Companies (EAEPC)
- European Association of Pharmaceutical Full-Line Wholesalers (GIRP)
- European Association of Pharmaceutical Full-Line Wholesalers (GIRP)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- European Medicines Agency (EMEA)
- Evolution Homecare
- Federal Trade Commission (FTC)
- Food and Drug Administration (FDA)
- Galenica A.G.
- GlaxoSmithKline
- Guangzhou Pharmaceuticals Corporation
- Healthcare Distribution Management Association (HDMA)
- Hedef Alliance Holding A.S.
- HeidelbergCement AG
- International Federation of Pharmaceutical Wholesalers (IFPW)
- Kohlberg Kravis Roberts & Co.
- Lloydspharmacy
- London Stock Exchange
- McKesson Corporation
- Medco Health Solutions Inc.
- Medicaid
- Medicare
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- MegaPharm
- Merckle Group GmbH
- Movianto
- Nadro S.A de C.V.
- NanoGuardian
- Napp
- National Association of Wholesalers (NAW)
- National Coalition for Pharmaceutical Distributors
- National Health Service (NHS)
- Novo Nordisk
- Office of Fair Trading (OFT, UK)
- Parata Systems
- Pfizer Inc.
- Pharmaceutical Security Institute (PSI)
- Pharmaceutical Services Negotiating Committee (PSNC)
- Quality King Distributors Inc.
- Ratiopharm GmbH
- Rite Aid Corporation
- Roche
- Safeway Inc.
- Supreme Distributors Company
- Tamro Group
- Target Corporation
- Teva Pharmaceutical Industries Ltd
- The Bank of England
- The Medicine Shoppe
- The Phoenix Group
- UniChem
- US Securities and Exchange Commission (SEC)
- Victory Wholesale Grocers Co.
- Walgreens Co.
- Wal-Mart Stores Inc.
- World Health Organisation (WHO)
- Wyeth Pharmaceuticals

Pharmaceutical Market Research

Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis